Univo Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
Univo Pharmaceuticals has been growing earnings at an average annual rate of 40.4%, while the Biotechs industry saw earnings growing at 12% annually. Revenues have been growing at an average rate of 73.4% per year.
Key information
40.4%
Earnings growth rate
57.8%
EPS growth rate
| Biotechs Industry Growth | -24.5% |
| Revenue growth rate | 73.4% |
| Return on equity | -159.2% |
| Net Margin | -73.3% |
| Last Earnings Update | 30 Jun 2022 |
Recent past performance updates
No updates
Revenue & Expenses Breakdown
How Univo Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 22 | 44 | -32 | 20 | 3 |
| 31 Mar 22 | 47 | -6 | 20 | 4 |
| 31 Dec 21 | 42 | -6 | 20 | 4 |
| 30 Sep 21 | 38 | -3 | 19 | 3 |
| 30 Jun 21 | 43 | 0 | 16 | 3 |
| 31 Mar 21 | 34 | -4 | 13 | 3 |
| 31 Dec 20 | 34 | 0 | 10 | 2 |
| 30 Sep 20 | 24 | -1 | 10 | 2 |
| 30 Jun 20 | 11 | -5 | 10 | 1 |
| 31 Mar 20 | 6 | -8 | 10 | 2 |
| 31 Dec 19 | 1 | -12 | 11 | 2 |
| 30 Sep 19 | 0 | -34 | 8 | 2 |
| 30 Jun 19 | 0 | -56 | 6 | 1 |
| 31 Mar 19 | 0 | -56 | 4 | 1 |
| 31 Dec 18 | 0 | -57 | 2 | 0 |
Quality Earnings: UNVO is currently unprofitable.
Growing Profit Margin: UNVO is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UNVO is unprofitable, but has reduced losses over the past 5 years at a rate of 40.4% per year.
Accelerating Growth: Unable to compare UNVO's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: UNVO is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (6.6%).
Return on Equity
High ROE: UNVO has a negative Return on Equity (-159.2%), as it is currently unprofitable.